NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PFIZER · data 2026-11-01
PFIZER LIMITED
In plain words
Price: 30.9% below its 52-week high of ₹5,339.
Delivery: 52.7% of traded shares were kept for delivery over the last 10 sessions, against 56.2% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,570 cr |
| Net profit (last 12 months) | ₹735 cr |
| Sales growth, 3 years (yearly) | 1.3% |
| Profit growth, 3 years (yearly) | 5.0% |
At a glance
P/E 22.9, dividend yield 2.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 17.2%, ROCE 20.0%, operating margin 34.4%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth 5.0% and sales growth 1.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Healthy operating margin (34.4%).
- Pays a dividend yielding 2.0%.
- Slow sales growth (1.3% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 52.7% over the last 20 sessions vs 62.4% in the 40 before (0.84x); shares delivered per day 0.4x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 4 schemes hold it, about ₹664 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 17 Jul 26Dividend Dividend ₹75 (ex-date) -2.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is PFIZER LIMITED debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is PFIZER LIMITED's P/E ratio?
About 23, based on the last 12 months' earnings and a price of ₹3,687.8 (data 2026-11-01).
What is the 52-week high and low of PFIZER LIMITED?
The 52-week high is ₹5,339 and the 52-week low is ₹3,589.
Mutual funds holding PFIZER LIMITED
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹664 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA SMALL CAP FUND | Nippon India Mutual Fund | 0.58% | ₹469 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.35% | ₹124 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 1.97% | ₹60 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.01% | ₹11 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
| Caplin Point Laboratories Limited | ₹2,325.6 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +15.2% |
| Alivus Life Sciences Ltd | ₹1,415.3 | ₹17,284 cr | 26 | 4.8 | 18.4% | 22.4% | 0.02 | +55.2% |
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| Eris Lifesciences Ltd | ₹1,156.4 | ₹16,088 cr | 22.5 | 3.9 | 18.3% | 15.6% | 0.6 | -29.0% |
| AstraZeneca Pharma India Limited | ₹6,364.5 | ₹15,918 cr | 93.8 | — | 23.9% | 25.5% | 0.13 | -31.8% |
Compare PFIZER with CAPLIPOINT in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PFIZER in NSE Scanner →